Effectiveness of nirmatrelvir/ritonavir in children and adolescents aged 12–17 years following SARS-CoV-2 Omicron infection: A target trial emulation
: Paxlovid on over 49k children with covid-19, non-hospitalized
Paxlovid treatment was associated with reduced 28 day all-cause hospitalization (absolute risk reduction = 0.23%, 95%CI = 0.19%–0.31%; relative risk = 0.66, 95%CI = 0.56–0.71).
No events of mortality, in-hospital disease progression, or adverse clinical outcomes were observed among paxlovid users.